Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Eli Lilly & Co ( (LLY) ).
At the 2025 Annual Meeting held on May 5, Eli Lilly & Co shareholders voted on several key issues. Four directors were elected for three-year terms, executive compensation was approved, and Ernst & Young LLP was ratified as the independent auditor for 2025. However, proposals to amend the Articles of Incorporation to eliminate the classified board structure and supermajority voting provisions did not pass.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
Eli Lilly & Co scores a solid 72, driven by strong financial performance and a positive earnings outlook. The company’s robust revenue growth, effective cash management, and strategic investments in manufacturing bolster its position. However, high leverage and valuation concerns, along with mixed technical indicators, suggest a need for cautious optimism. The company is poised for growth, yet investors should monitor potential regulatory and market challenges.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
Eli Lilly & Co is a pharmaceutical company that focuses on developing innovative medicines for various health conditions.
Average Trading Volume: 3,851,164
Technical Sentiment Signal: Buy
Current Market Cap: $734.6B
See more data about LLY stock on TipRanks’ Stock Analysis page.